Cargando…

Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours

Telatinib (BAY 57-9352) is an orally available, small-molecule inhibitor of vascular endothelial growth factor receptors 2 and 3 (VEGFR-2/-3) and platelet-derived growth factor receptor β tyrosine kinases. In this multicentre phase I dose escalation study, 71 patients with refractory solid tumours w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strumberg, D, Schultheis, B, Adamietz, I A, Christensen, O, Buechert, M, Kraetzschmar, J, Rajagopalan, P, Ludwig, M, Frost, A, Steinbild, S, Scheulen, M E, Mross, K
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2008
Materias:	Clinical Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2584942/ https://www.ncbi.nlm.nih.gov/pubmed/19002179 http://dx.doi.org/10.1038/sj.bjc.6604724

Ejemplares similares

Phase I study of telatinib (BAY 57-9352): analysis of safety, pharmacokinetics, tumor efficacy, and biomarkers in patients with colorectal cancer
por: Mross, Klaus, et al.
Publicado: (2011)

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study
por: Strumberg, D, et al.
Publicado: (2012)

A clinical phase II study with sorafenib in patients with progressive hormone-refractory prostate cancer: a study of the CESAR Central European Society for Anticancer Drug Research-EWIV
por: Steinbild, S, et al.
Publicado: (2007)

Pharmacogenetics of telatinib, a VEGFR-2 and VEGFR-3 tyrosine kinase inhibitor, used in patients with solid tumors
por: Steeghs, Neeltje, et al.
Publicado: (2009)

Discovery of SHR9352: A Highly Potent G Protein-Biased μ-Opioid Receptor Agonist
por: Li, Xin, et al.
Publicado: (2017)

A randomised phase II trial of the Polo-like kinase inhibitor BI 2536 in chemo-naïve patients with unresectable exocrine adenocarcinoma of the pancreas – a study within the Central European Society Anticancer Drug Research (CESAR) collaborative network
por: Mross, K, et al.
Publicado: (2012)

Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
por: Frey, Reiner, et al.
Publicado: (2011)

Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours
por: Awada, A, et al.
Publicado: (2005)

Phase I dose-escalation studies of roniciclib, a pan-cyclin-dependent kinase inhibitor, in advanced malignancies
por: Bahleda, Rastislav, et al.
Publicado: (2017)

Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study
por: Schultheis, B., et al.
Publicado: (2013)

B-Quark-Tagging mit neuronalen Netzwerken
por: Buechert, Martin
Publicado: (1992)

Pharmacokinetics and pharmacodynamics of acetylsalicylic acid after intravenous and oral administration to healthy volunteers
por: Nagelschmitz, J, et al.
Publicado: (2014)

440. Detection of COVID-19 Patients Requiring Escalation to ICU Status Using a Naïve Bayes Classifier
por: Barnett, William R, et al.
Publicado: (2021)

A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours
por: Siegel-Lakhai, W S, et al.
Publicado: (2008)

Bayes or not Bayes, is this the question?
por: K. Hackenberger, Branimir
Publicado: (2019)

Escalated handling of young C57BL/6 mice results in altered Morris water maze performance
por: Fridgeirsdottir, Gudrun Andrea, et al.
Publicado: (2014)

A phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors
por: Mross, Klaus, et al.
Publicado: (2016)

Real de-escalation or escalation in disguise?
por: Banys-Paluchowski, Maggie, et al.
Publicado: (2023)

Oxaliplatin-DNA adduct formation in white blood cells of cancer patients
por: Pieck, A C, et al.
Publicado: (2008)

Distribution and tumour cytotoxicity of the radiosensitizer misonidazole (Ro-07-0582) in C57 mice.
por: Pedersen, J. E., et al.
Publicado: (1979)

Interleukin-6 (IL-6) serum concentrations in dogs with hepatitis and hepatic tumours compared with those with extra-hepatic inflammation and tumours
por: Neumann, Stephan, et al.
Publicado: (2010)

Tolerability of a rapid‐escalation vinblastine‐prednisolone protocol in dogs with mast cell tumours
por: Serra Varela, Juan Carlos, et al.
Publicado: (2016)

Phase I study of dose-escalated paclitaxel, ifosfamide, and cisplatin (PIC) combination chemotherapy in advanced solid tumours
por: Kosmas, C, et al.
Publicado: (2000)

Bayes and empirical Bayes methods for data analysis /
por: Carlin, Bradley P.
Publicado: (2000)

Bayes and empirical Bayes methods for data analysis
por: Carlin, Bradley P.
Publicado: (1998)

Clinical analysis of Krukenberg tumours in patients with colorectal cancer—a review of 57 cases
por: Xu, K. Y., et al.
Publicado: (2017)

Incoherent dose-escalation in phase I trials using the escalation with overdose control approach
por: Wheeler, Graham M.
Publicado: (2016)

In Vivo Fat Quantification: Monitoring Effects of a 6-Week Non-Energy-Restricted Ketogenic Diet in Healthy Adults Using MRI, ADP and BIA
por: Buechert, Martin, et al.
Publicado: (2020)

The Chemical Induction of Breast Tumours in C57B1, IF and F(1) Hybrid (C57B1×IF) Breast Tissue Transplanted into Breast Free F(1) Hybrid (C57B1 × IF) Hosts
por: Riggott, J. M.
Publicado: (1965)

Escalate and De-Escalate Therapies for Intracranial Pressure Control in Traumatic Brain Injury
por: Battaglini, Denise, et al.
Publicado: (2020)

Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study
por: Hong, D S, et al.
Publicado: (2019)

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study
por: Isakoff, S J, et al.
Publicado: (2014)

Bayes and Empirical Bayes Estimators of Abundance and Density from Spatial Capture-Recapture Data
por: Dorazio, Robert M.
Publicado: (2013)

A dose escalation and pharmacokinetic study of biweekly pegylated liposomal doxorubicin, paclitaxel and gemcitabine in patients with advanced solid tumours
por: Bozionelou, V, et al.
Publicado: (2007)

Parenteral nutrition in oxygen escalation/de-escalation in SARS-CoV. When and how?
por: Quintero O, Oscar Iván, et al.
Publicado: (2022)

Extinction Risk Escalates in the Tropics
por: Vamosi, Jana C., et al.
Publicado: (2008)

Behavioral Response of Corophium volutator to Shorebird Predation in the Upper Bay of Fundy, Canada
por: MacDonald, Elizabeth C., et al.
Publicado: (2014)

A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted olid tumours
por: Adenis, A, et al.
Publicado: (2013)

Escalation and de-escalation of mechanical circulatory support in cardiogenic shock
por: Bertoldi, Letizia F, et al.
Publicado: (2021)

Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol
por: Pigorsch, Steffi U., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_en1u9iano63osj68a4qbvotq7m